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¶1

¶2

MR. NARAYEN: Thanks, everybody, for coming. We are going to get started
right now. Just to introduce myself, I am Vishesh Narayen. I am Editor in Chief of the
Northwestern Journal of Technology and Intellectual Property. I would like to welcome
everybody to our Fifth Annual Symposium. Before we kick off, I would like to give a
little background about the Journal, where we have been and where we are going. The
Journal is going to be finishing the publication of its eighth issue this year. We have been
around for just under a decade, and in that time we have been cited by Congress. We
have published Journal articles that have been cited by the Federal Circuit. In addition,
numerous other law reviews and journals have cited our publication. And I think because
of our close relationship with the practitioner community, we really are at the cutting
edge of IP and technology law. And, of course, all this is made possible by the
dedication of our staff and our members, the support of Northwestern Law, and the
support and the generosity of our sponsors.
And on that note, I would like to specifically thank our sponsors today. McDonnell
Boehnen Hulbert & Berghoff is our platinum sponsor. They have generously returned as
a platinum sponsor this year, and they have been very helpful in offering ideas for today's
symposium and to help plan for it. I would like to thank them for that. We actually have
a number of MBHB attorneys today on panels: Daniel Williams, Michael Baniak, who is
also an adjunct here, Donald Zuhn, and Joseph Herndon, who you will see during the
panels today. I would also like to thank Knobbe Martens Olson & Bear, who is our gold
sponsor. They have also stepped up again this year, and we really appreciate that. We
hope it is a continuing relationship that we will have with them. Nicholas Zovko from
their Riverside, California office is here today. He's come a long way to join us. He will
be participating in our afternoon panel on USPTO and rule making. I would also like to
recognize our silver sponsors, Goodwin Procter and McAndrews, Held & Malloy. We
greatly appreciate their support, and we hope they will continue to think of us in the
future.
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I would like to give special thanks to Evan Boetticher. He's worked tirelessly since
last fall to put this all together, and I think it will show in how well organized it is, and I
think that's a credit to him. I am sure he will be taking a well-deserved break at the end
of the day. Two quick administrative announcements before we get started. If any
attorneys would like to get CLE credit for attending today's events, the forms are outside.
Just make sure you get a chance to fill them out before you leave. Also, we are starting
an e-mail distribution list to announce publication of each issue as well as other events,
like this symposium. If you would like to receive those announcements, please be sure to
sign up outside. The form is right outside the door. At this time, I would like to welcome
the dean of Northwestern University School of Law, Dean Van Zandt.
MR. VAN ZANDT: Thanks, Vishesh. This is an ongoing conference. It's
happened every year. I think it's a fabulous thing for the Law School. Certainly, I add my
thanks to Evan, because I know what a lot of work it is, and I know what a great job he's
done. In fact, the first panel and I were just discussing it, and outsiders were
complimenting on how well it was organized. So I think you should take that to heart. IP
technology is becoming more and more important. Here at Northwestern, we have seen,
actually, an increase in the percentage of our entering students who come with technical,
science, or engineering backgrounds. And we have quite a few people who have worked
in the industry before they came to the Law School. So it's something that I see is going
to be a growth area for a long, long time. In fact, if you look at the information about the
legal services industry and where there's been growth in the last couple of years with the
economic downturn, the latest reports show that revenues in the industry are down about
10 percent in 2009. There's continued to be growth in the IP area, whether it's IP
litigation or other types of IP work. I don't see that stopping in the way technology keeps
moving forward.
One of the things relevant to the legal services industry is the case In re Bilski,
which you are going to hear something about on the first panel. This patent issue is one
that a lot of law firms are starting to look at in terms of whether they can do things that
are actually protectable. They are looking at whether they can either sell or otherwise
take advantage of various kinds of research, various kinds of forms, kinds of methods of
actually doing the practice of law that may be patentable in the future, depending upon
the outcome of In re Bilski. The last thing I want to say is something of an
announcement. We are right now in the process of discussing with McCormick School
of Engineering an arrangement in which we would have a number of McCormick faculty
here doing for-credit technology briefings in different areas for our students. That will be
a real addition to the students interested in various types of IP. The idea is to have a
different way to inform our students about issues in biotech, computer science, electrical
engineering type things, or even civil and mechanical engineering because our students
end up being out there. They have to understand that stuff anyway, and they have to
learn about it, and it's good to have, at least, a good briefing to start off with. So I am
very pleased about that.
Finally, I would like to thank Sharon Barner. Thank you for joining us today and
being with us and being our keynote speaker. If you have some free time, please come
over to the Law School. We are right next door. We have a lot of things going on in the
Law School. This building is a mixed building between Kellogg and the School of
Continuing Studies. Come over to our main building and look around. I think we have a
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beautiful Law School. So again, congratulations to Evan, Vishesh, and the rest of the
Board for putting this together. I think it will be a great day. Thank you.
¶7
MR. BOETTICHER: I would like to thank the Dean for his kind words, and we
appreciate you starting off what we hope to be a wonderful symposium. Our first panel
today concerns a case that has spanned the length of my legal education. On April 10,
1997, Bernard Bilski and Rand Warsaw applied for a patent for initiating purchases and
sales of commodities at fixed prices for the reduction of risk. Rather than rejecting the
patent for obviousness, the examiner rejected the purely business patent as unpatentable
subject matter. The case was heard before the Federal Circuit in October of 2007, one
month after my class started law school. An en banc Federal Circuit heard the case May
of 2008. After rejecting two other possible standards for patentability, the Federal Circuit
ruled the application unpatentable, because it was not linked to machine or
transformation. This was not without its dissenters. Last November, the case was argued
before the Supreme Court. And at the pace things are going, we may not have a result
until after I have graduated, making our dearly-paid-for education obsolete faster than we
originally anticipated.
¶8
Today we have four excellent panelists that we expect to supplement all of our
education. Daniel Williams is a practitioner in this field, who graduated with a degree in
computer engineering from University of Michigan, and received a law degree from
Harvard Law. Mr. Williams is experienced in a number of technical areas, including
software development, operating systems, and microprocessor architecture, as well as
both patent and trade secret litigation. Mr. Williams is also the editor of MBHB's
Snippets newsletter. Jonathan Masur currently teaches administrative law, patent law,
behavioral law, and legal theory at University of Chicago.
¶9
Professor Masur received a B.S. in physics, an A.B. in political science from
Stanford University, and a J.D. from Harvard Law. After law school, Professor Masur
clerked for Judge Posner of the 7th Circuit, and Chief Judge Patel of the U.S. District
Court of the Northern District of California.
¶10
Matthew Sag is a professor at DePaul University College of Law here in Chicago.
He's also been a visiting professor at University of Virginia School of Law and here at
Northwestern University. Professor Sag has a varied and international background. He
acquired his law degree with honors from the Australia National University and went on
to practice law in the United Kingdom and Silicon Valley. Professor Sag is the co-author
of the recent article "Taking the Measure of Ideology: Empirically Measuring Supreme
Court Cases," in which he considered the effects of ideology on how the Supreme Court
rules in intellectual property cases.
¶11
Finally, we have Joshua Sarnoff. Professor Sarnoff is a graduate of MIT and
Stanford Law, who currently is a professor at Washington College of Law, American
University, where he teaches patent law, and is visiting at the DePaul University College
of Law.1 Professor Sarnoff has written numerous articles and book chapters on patent
law and has been involved in a wide range of intellectual property legal and policy
disputes, including filing an amicus brief on In re Bilski when it was at the Federal
Circuit and in the Supreme Court.

1

At the time of this Symposium, Professor Sarnoff taught at Washington College of Law, American
University. Currently, Professor Sarnoff teaches at DePaul University College of Law.
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I would like to thank all of you for coming today. I would like to thank our
attendees, and I invite the audience to take part in a conversation and open discussion in
which we will review the possibilities for the Bilski decision before the Supreme Court. I
would like to take this opportunity by starting off the questions by asking Mr. Williams,
for starters, and move down the line. What's the big deal? If the Supreme Court does
uphold the machine-or-transformation test, that's not necessarily the end of business
patents, is it? Because business patents could still be linked to a machine fairly easily.
So what would really be the long-term effects of them overruling the machine-ortransformation test?
MR. WILLIAMS: I think it would have an impact. I think it would have an impact
on claims like the claim in Bilski, claims of tax strategies, particular business models,
such as a pyramid scheme or something like that or a different way of putting together a
business' architecture. I think there are a number of things that wouldn't be easily tieable
to a computer implementation. So I think it would have quite an impact. So that's my
initial take.
PROFESSOR SAG: I was going to say, the question is, really, do we lose anything
that we don't want to lose? I think from the perspective of the live software companies,
they can and do patent all their inventions in a number of different ways, and for most
companies, Bilski is only going to strip out some claims of some patents if machine-ortransformation is upheld. The real question is, do we lose anything by no longer having
patents on things like tax strategies and, methods of legal practice?
PROFESSOR MASUR: First of all, I want to say thanks to Evan for organizing
this. It's exciting to be on a panel with people who know so much about the issue. One
thing I think I want to highlight is that, in my mind, the major question that faces the
Supreme Court if, as seems likely, they are going to adopt some version of the machineor-transformation test, is whether or not they are going to permit general purpose
computers to fulfill the machine part of that machine-or-transformation test. So the
original Federal Circuit opinion in Bilski was, sort of, ambiguous on that issue. It didn't
really state quite clearly whether a general purpose computer would satisfy the machine
element, and Bilski's patent doesn't include a computer as part of it.
Immediately after Bilski, the Patent and Trademark Office through the Board of
Patent Appeals and Interferences handed down a series of rulings which indicated it did
not think that a general purpose computer was adequate to satisfy the machine-ortransformation test. And then, within a matter of months, the BPAI reversed itself. And
so the standard in the BPAI, when combined with Bilski, was that a general purpose
computer was, in fact, sufficient to satisfy the machine-or-transformation test.
I would say this is the whole shooting match: if a general purpose computer is
enough, then nearly everything is in bounds. Software is in bounds. Lots of tax
strategies, although, maybe not all, are in bounds. A lot of the methods—standard
business methods, including the sort of thing that Bilski wants to do, are in bounds also.
The vast majority of the commercially viable sorts of things that people want to patent
that we would call business methods or tax strategies, or anything of the like, have to be
performed on a computer. If a general purpose computer is excluded, then all of a sudden
all of these things might be very difficult to patent, or they might have to be tied to
particular types of machinery that will really limit the scope of the patent in important
ways. So at that point, business methods, tax strategies, software patents all become
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substantially less useful, less powerful property rights. They may protect particular
applications using particular pieces of hardware, but they are not going to be particularly
strong in terms of general coverage, and a lot of them may not be obtainable at all.
Software patents, for instance, might be next to worthless at that point.
There's a question then at that point about whether we think that those are the sorts
of things that are worth losing or may be beneficial to have lost. And I think that Matt
has raised all the right questions about that. But I do just want to highlight that the
Supreme Court faces a clear crossroads here. And there are indications that the Court
may shy away from making categorical statements about the applicability of the general
purpose computer, and whether that is sufficient or not. It may want to push that issue
aside or leave it for another day, in which case it might very well be, depending on the
behavior of the Federal Circuit and the Board of Patent and Interferences, that the
floodgates will remain open, and potentially everything that was patentable before Bilski
will remain patentable after Bilski, as long as there's some clever drafting.
PROFESSOR SARNOFF: Most of what I have to say is very similar to Professor
Masur. The actual language is a “particular machine,” and you have to figure out
whether the Supreme Court is going to say anything about the nature of the invention,
and whether different kinds of claim drafting, where you add other pieces of structure or
add things that you do the processes on, is really part of the invention for patenting. Then
you have the question—whether those things are things you actually want to protect. But
it's not just general purpose computers. Looking back at BPAI decisions, there's actually
a fairly good summary from 2009 by Sterne & Kessler. You have databases. You have
displays of data. You have software. With a few of them, the BPAI is acting
inconsistently, but by and large those types of additional structures were found not to be a
“particular machine” implementation.
The much more interesting question is Beauregard claims. And you have directly
inconsistent panel rulings as to whether or not the software, which is really just a program
set of instructions—that's where the invention is—is the type of thing that can be
patented when reduced to a tangible medium of some sort. It's an interesting question.
And this goes back to the heart of the Supreme Court's difficulty between Flook and
Diehr. You have what's clearly an article of manufacture, which is a hard drive, for
example. That's not the invention. The invention is the software. If you put the software
on the hard drive and claim them together, do you have now an article of manufacture as
your invention or do you just claim the software in an article of manufacture? That's
what the Supreme Court has got to figure out: what's the invention? How is it being
claimed, and are we going to allow the additional structures to change the nature of the
invention for purposes of patenting. We really don't know what they will do with these
questions.
MR. WILLIAMS: This makes me wonder how much is really on the table for the
Supreme Court to decide here because the Federal Circuit really said that there's the
machine-or-transformation test. Clearly Bilski's claim has no machine; so this is a
transformation case. Not only that, but they wrapped the process circle around the entire
case. So I am just wondering if they will even weigh in on these other statutory
categories. It seems intellectually like it should be the same analysis. If you can or
cannot get a patent on a process that's operated by—that's just a computer operating
software—shouldn't it be the same result if you claim it as a computer having the
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following software, or a computer readable medium having the following software, or
software where the rest of the claim is exactly like a method claim would look? So all
these things intellectually seem equivalent, but I was wondering procedurally if the
Supreme Court is even going to feel like those are issues that are presented to them in this
case.
PROFESSOR SARNOFF: Certainly, the U.S. Government said, “Don't go near
these issues.” From the argument, as I have wrote in a blog post, I had the feeling that
that the Courts would rule extremely narrowly, at least for whatever the majority or
unanimous holding of the Court is. There may be concurrences. They may start hitting
on some of those issues, but, again, those won't be a majority–just a large plurality of
concurrences. So I think you will be left with a desire for more guidance that won't come
out of this case.
PROFESSOR MASUR: I think that the Court feels as though its role here is to
scale back on the granting of business patents and other things of the sort. So I think
there are genuine desires for a narrow holding. And these sorts of questions of the
Federal Circuit will be tempered only by the felt need to actually take some sort of a step
against widespread patenting of software, tax patents, et cetera. And the Court really sees
its role—the Roberts Court, especially in the last several years—has really seen its role as
pushing back against what it views as over-patenting in the Federal Circuit and excessive
permissiveness there. And so my sense is that the Court would not—I mean, one thing
the Court could do is simply reaffirm the machine-or-transformation test, and leave all of
the details to the Federal Circuit and the PTO. I don't think that is the easiest outcome.
That may be the most likely outcome, but I think that the Court will hesitate at that,
because I don't think they will believe that that will represent a sufficient curb on what
they view as excessive patenting. It will feel the need to reach out and try to do a little
more, despite the fact that a lot of parties, including the Government, have been trying to
push it to stick to the very basic outlines of formulating the proper test.
PROFESSOR SAG: I think that the Supreme Court probably went into the Bilski
case wanting to do more. But one may suspect, after looking at the oral argument and
briefs, that they may realize doing more is more difficult than they thought. So if we see
an affirmation of machine-or-transformation, we are at best going to see some general
guidance that, I think, is still going to push most of this back down to the Federal Circuit.
I just don't think that the way forward looked particularly clear at the end of oral
argument for—the critical question is, machine or transformation? Tell me again what a
machine is. Tell me again what a transformation is or isn't. I would be very surprised if
they said anything that was particularly specific. I think they are going to have to push
this back to the group of people who are probably least able to deal with it, which is the
Federal Circuit.
MR. WILLIAMS: I think there's a tension between these comments and the fact
that they took the case at all. Because in a non-patent situation, where there's multiple
Courts of Appeals, such as the 9th Circuit, 5th Circuit, etc., often the Supreme Court
takes a case because there's a split. But in the Federal Circuit context, it's a single court
that they are deciding whether or not to grant cert. on a case—on a decision from the
Federal Circuit. So it seems to me that they wouldn't do it if they think the Federal
Circuit got it right. I know it only takes four justices to grant cert. So I would say at least
four of them think they didn't get it right. There's just been a history recently with KSR
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and Festo and some other cases where the Federal Circuit has done something in the
name of certainty; said this is the test. This is it. And the Supreme Court said, “No, it
isn't.” That isn't the only test. And the teaching-suggestion-motivation issue in KSR is
very analogous to this.
So if the Supreme Court's goal is to curb overpatenting, I don't know that they
would have granted cert on a case where the Federal Circuit said no to a claim. I think
that what's likely to happen, at least in my view, is something similar to KSR. In KSR,
they said if the prior art contains teaching-suggestion-motivation, that can be enough to
show obviousness or a reason to combine. But the absence of it doesn't necessarily show
the absence of reason to combine. I think this case may come out the exact same way,
where they say, yes, if something passes the machine-or-transformation test, fine—it
passes 101. But if it doesn't, that doesn't mean it doesn't pass 101, and that—I don't know
that they will give much guidance other than that, and that they will probably agree—I
would think they would agree that this claim does not meet the standard of 101. But I am
guessing they will just find some precedent of theirs where they say that claims or ideas
that are too abstract or too abstractly stated are not patent eligible, and just leave it at that.
I am not sure how much further they can go. Who knows what they will do, of course.
But at least that's my guess about approximately what the decision will say.
MR. BOETTICHER: So at the Federal Circuit level, the Federal Circuit rejected
two other possible systems for determining patentability. So going back to what you
were just saying, Mr. Williams, is it possible that they might go back to those or say that
machine-or-transformation is one standard, and if you don't meet that, then it's possible
we will use the other standards? Are they going to create a hierarchy? Are the other two
standards that the Federal Circuit, sort of, pushed aside, are they still viable, do you think,
or do you think that they are out of the picture at this point?
MR. WILLIAMS: I am not sure whether they will revert to a test, because I am not
sure that they ever had a test. And I think even the Federal Circuit wasn't quite sure. It's
just a very weird decision, the Bilski Federal Circuit opinion, because they say, we have
looked at all the Supreme Court cases, and what comes out of that is that the machine-ortransformation test is definitely the test, even though the Supreme Court said, well, not
necessarily. And then they decided that was the test, and then projected their test back on
the Supreme Court cases, and gave themselves an “A” for their effort. And even in the
Federal Circuit decision, the quote that you would quote in every brief that says what the
test is coming out of the Federal Circuit decision, includes a word that just drives me
crazy. It says, "A processed claim is surely patent eligible." Surely. If it passes the
machine-or-transformation test. So they, basically, came down with a decision that said,
this is the test. If it passes this, it is patent eligible. If it doesn't pass this, it's not. But
then their own phrasing of that test, basically, says that passing the test is sufficient, but
not necessary. So it's a mess, I think.
PROFESSOR SARNOFF: I have a couple of thoughts. First, why did the
Supreme Court take it at all? It was an exceptional case, in part, chosen by the Federal
Circuit to pull back from the broadest expansion that they had themselves created. They
took it en banc, on their own, after argument and before a panel decision, which almost
never happens. There were a couple of other exceptional features about the case. It was
also timely, I think—and particularly after LabCorp, the Court had signaled they wanted
another subject matter. The time was right; it just may not have been the best case to
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take, even though it was set up, this vehicle, earlier. I totally agree with your thoughts
about KSR as the model.
The problem is that when you have a test and you say it's not the exclusive test, and
you are saying that it fails that test, then you have to come up with some other thing on
which to reject the claim as not being patentable subject matter. They don't have a theory
here of what, other than machine-or-transformation, makes something patentable, and
that's where you are going to get, I think, the concurrences articulating different theories:
the technological arts test possibly, and the abstract idea test possibly, and the abstract
idea test possibly. Since Justice Stevens wrote Parker v. Flook, I assume he hasn’t
changed his view that it's a point of novelty test. You need something that is more than
extra-solution activity test, and this doesn't meet it. But no test is going to command a
majority of the Court for any of those theories.
So what would the Court do in saying that the invention is not a machine-ortransformation, but it's still not patentable. The only thing I can think of they might do
that might pull together nine votes is to say that it just doesn't look like anything we have
seen before that we have allowed. It's not like an industrial process and, therefore, it just
isn't patentable. My sense is they will analogize to old cases and not come up with
anything that's theoretically capable of being extended. And then we are back to the
Federal Circuit. What do they do?
PROFESSOR MASUR: The verbal formulation the Supreme Court chooses, I
think is a lot less important than particular details of how that verbal formulation is
operationalized. So you can have a very lenient machine-or-transformation test. You can
have a very strict machine-or-transformation test. You can have a very lenient tangible
result test. I think the Federal Circuit said if they went with a tangible result test, it would
lead to widespread patenting, including on Bilski's patent. You could have a very strict
tangible result test, if you just define "tangible" in a very limited sort of way. So the
particularities are what, I think, are important in the question we are raising. And, to a
large degree, what we are in agreement on is that the Supreme Court has been having a
difficult time sorting out those particularities.
I think it's also worth noting, I don't think the Supreme Court has a lot of really
good options available to it, simply because all of these verbal formulations are not
particularly useful. So, it could make an actual technological—say something like,
nothing that is a business method can be patented. That raises all sorts of definitional
questions. It may open the door for creative patent drafting, and escaping from those
sorts of boxes. It could remove all limitations and just say anything that is useful and
novel is patentable. I think the Supreme Court doesn't want to do that and sees the patent
law going too far in that direction.
So now it's left with things like machine-or-transformation, with or without
computers, tangible result, results that are more or less tangible, and so forth, all of which
have their problems and all of which create lots of confusing issues that the Court
probably doesn't want to sort out on its own accord. So, it's a problem, in part, with the
institutional posture of the Supreme Court. It knows the direction that it thinks patent law
should go. It thinks there's been too much patenting, but it doesn't quite have the legal
tools to get there. And it doesn't trust the subordinate acts of the Federal Circuit well
enough. Because the whole point of this case and this whole line of cases the Supreme
Court has taken under the Roberts Court, Merck in 2005, and e-Bay in '06, then KSR, and
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MedImmune, AT&T, and Quanta, the whole point of all these cases is that the Federal
Circuit is not to be trusted to expand patent rights too far, too fast, too much. So I think
the Court is going to be in a real quandary. It might be that they are just going to take the
narrowest and simplest option, and opt for something that is, sort of, simple. But I think
they will do that with great regret because they don't trust the Federal Circuit to do a good
job.
MR. WILLIAMS: I think they want to tell the Federal Circuit that they were
wrong to say that this is the test. And I think they also want to say that this claim,
Bilski's claim one, is not patent-eligible subject matter, and that's a difficult road to walk.
But what I am hoping they do, and what I think, really, should be the central concept in
101 analysis, is abstraction. And this is kind of my pet issue when it comes to 101. I
don't think it should be analyzed exactly like enablement is in 112, but I think it should
be, basically, a threshold-like, “112-light” type analysis. I think we should go back to
first principles here, which is that the whole point of the patent system is that against the
backdrop of not liking monopolies in a free market capitalist economy, we will grant
them when we get the commensurate exchange from the inventor of enriching the public
with a description of how to do something. And I am not sure that claims like this can
hold up the inventors' end of the bargain, because as I read this—kind of just to back up
again for a second. So I really think that 112 is a test for whether or not the drafter or the
applicant has actually enabled their claim. And I sort of think 101 should be whether or
not they even could.
Again, with the big bargain that the patent system is supposed to be, in exchange
for your monopoly, you are supposed to give others in that field something that's
portable—kind of, portably useful, that they can take and use in their own business. And
as I read this claim, I don't know how you could give this to someone else in this field—
whatever this field is—commodity buying and selling, and that they could start from
there. I mean, that's the whole point of the patent system, is that someone should be able
to stand on the shoulders of what's come before. And this claim, to me—I would read
this and say, how do I do this? I mean, how do I identify these market participants? How
do I pick these rates? How do I strike this risk balance? You can't turn someone into a
good business person or a successful business person by telling them to manage their
risk, and to have some transactions and some other kinds of transactions that ultimately
arrive at a hedge position for your company.
First of all, that's not new. But I don't see how you could just tell someone to do
that, and then they would be able to do it. So that, to me, is—it's centering around this
idea of abstraction. And this is too abstract to be useful to anyone. And so I think it
should fail 101 for that reason. I am hoping that's what the Supreme Court says; that the
Federal Circuit got it wrong in saying that machine-or-transformation is the test. If you
pass it, fine. It satisfies 101. But if you fail it, you don't necessarily fail 101.
The question is, is what you are claiming too abstract to be enableable? And it just
makes me think that this whole preemption stuff that comes through in the Flook and
Diehr cases is a red herring. I think it gets it wrong because to me, you shouldn't get a
patent just because you are asking for less than what you thought of. And if you come up
with a foundational idea, then you deserve a patent with that level of scope, whether it
preempts everybody else from doing that or not. By definition, claims do that. They
preempt everybody else from doing what they say. And I think you can just track the
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cases where they said, yes, this preempts the use of this idea as saying this is too abstract.
And cases where they said this isn't preemption, it's a specific application, like the
Arrhenius equation in Diehr. And what they should have said in Flook with the alarm
limits is that it is not too abstract, because someone could actually take what you have
written and go do that, and not have to reinvent it. So, 101 analysis should be kind of like
a pre-112 analysis. Ask, is this even the kind of thing that could be enabled? And if it's
not, and it's too abstract, then it fails 101. That's, kind of, what I have been thinking
about.
PROFESSOR SAG: I don't disagree with what Daniel has said here, but I can't
help wondering that if all we are using subject matter eligibility for is to release patent
scope, then, perhaps, 112 becomes a little bit redundant with 101. In other words, if we
use enablement to police the scope of the patent claims and now are we just going to have
two different assessments, really, of patent scope, and no other guidance? Hopefully the
Supreme Court will say something useful that reinforces that claims that are too abstract
are not patentable subject matter. But if that's all that comes out of this, then it's going to
be disappointing.
MS. BARNER: This is the whole concept of scope when you are talking about
what's patentable, about line drawing. Where do you draw the line? But yet, when you
talk about the Federal Circuit actually trying to draw a line, the criticism is, you can't
have a line drawn so that you can give some clear guidance to people about what's
patentable and not patentable. So in light of all your discussion that you had, how do you
draw a line here?
PROFESSOR SARNOFF: This is why abstraction doesn't work very well, because
you have a level of generality problem, about what the actual invention is that you are
trying to claim now is too abstract. So take the claim at issue in Bilski. It could be that
the concept that one looks to for abstraction is hedging, or it could be that it's a fixed
price hedging, or it could be that it's commodities fixed price hedging, or it could be, as
claimed, the specific interaction methodology for fixed price commodities hedging. At
that last level, it probably is both useful, practical, and fully enabled. The question still
is, is this the kind of thing we want? It's not abstract in the same way that we think of
scope problems, because you are talking about a practical application of hedging. This is
why I agree.
Preemption analysis makes no sense at all, because all you are saying is you figured
out hedging. Now all you have to do is write 12 different claims to different applications,
and somehow you have avoided the eligibility problem. You swallowed the entire area in
small bites. If there's a problem with giving you rights on the big concept, there should
be a problem giving you rights on the small one. It is the same type of “thing,” even
though you have added details about how to limit its scope. So that's why line drawing is
not easy here. Line drawing isn't any easier under any of the other tests. So what is
technology? May I suggest that's not going to be an easy line. If we are going to do linedrawing—where is the invention, and where is the extra-solution activity? That's not an
easy one. It's all about line drawing. Now the question is, what kind of line are they
going to give us? I think the unfortunate thing about this case is that when they give us a
holding—they are not going to give us a rationale that helps draw the lines in other cases.
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AN AUDIENCE MEMBER: Rather than a pre-112 analysis, why not just go
straight to 112 or straight to 103, and if it passes those, then do 101? Why is 101
necessarily the first hurdle that has to be jumped for patentability?
MR. WILLIAMS: That brings to mind the fact that the Federal Circuit said in their
Bilski decision, I think, that 101 is a threshold, and you have to pass that before you even
get to the rest of them. But, I mean, that, to me, is just a question of what order you
evaluate these things in. They are all threshold inquiries. You have to pass 112. You
have to pass 102 and 103. Intellectually, it may make sense to not have 101, but it's there.
And so maybe all it should be is just evaluating whether or not this thing that you are
claiming fits one of those four categories that's listed in 101, and then get on to
enablement and novelty and non-obviousness, and figure out whether you deserve a
patent.
PROFESSOR MASUR: I don't think there is any particular reason to conduct one
of these inquiries first. That's what's so odd about Bilski's patent. Even if he wins
somehow, improbably enough, in the Supreme Court, he is never going to get a patent,
because the thing is obvious. So I don't know why. It almost seems like they invited the
rule that 101 is the threshold inquiry just so they could frame the question, and it could be
taken up to the Courts. And I want to say something about the line drawing question. I
agree with Josh that these are extremely hard lines to draw; maybe harder here even than
in many other areas in patent law, just because the boundaries between areas of
technology or between what's tangible and what's not are so fluid, and because with
clever claim drafting, people are going to be able to skirt those boundaries reasonably
effectively. For an effective line to be drawn, it's going to have to be drawn with a great
deal of particularity. It's going to be almost impossible to come up with a one-sentence
or one-paragraph verbal formulation. Somebody is going to have to make some hard
decisions about technology.
I would say also that we are doing ourselves a disservice if we concentrate only on
the types of lines that the rather ill-equipped Supreme Court and the completely
untrustworthy Federal Circuit are going to draw. An even more important question might
be, who else might we want to have drawing these lines? And I should say that the
Federal Circuit has done such a mediocre job of setting these boundaries so far that I
think it's time to reopen the inquiry into whether Congress should become more heavily
involved in these sorts of questions or whether the Patent and Trademark Office is the
right forum for trying to make these distinctions. I would be much more interested in
seeing the PTO experiment with drawing lines between patentability and nonpatentability than having the Federal Circuit muddle through with verbal formulation
after verbal formulation.
Although, I agree with the practical fact that it doesn't look like Congress is going
to pass legislation anytime soon. We are stuck in this world of second best, in which we
have the Courts acting and filling the area, simply because Congress isn't capable of
getting there itself. And as for the PTO, the PTO has never actually had the authority to
make these sorts of rules on its own accord without being second-guessed by the Circuit
Courts or the Federal Circuits after 1982 in all of the particulars. So given the
opportunity to actually make rules that stuck, that the Federal Circuit wasn't just going to
overturn, I think that there's no reason to believe the PTO would do any worse a job than
the Federal Circuit has been doing already, and a much better one. I think at this point
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it's worth trying because, to my mind, the tools of common law adjudication that the
Federal Circuit is employing here is not up to the task of making these distinctions
between what sorts of patents we want granted.
PROFESSOR SAG: There is one issue in here that probably won't even be
mentioned in the Supreme Court's decision, and that is Article 27—of the TRIPS
Agreement. TRIPS is part of WTO framework. It's the trade-related aspect. And that
article requires that patents shall be available, regardless of field of endeavor, regardless
of the field of technology. And I think it's going to be difficult for Congress, consistent
with our international agreements, to write the kind of legislation that people who want to
see subject matter restricted would have them write. I think pushing these decisions
down to courts is easier; it's just harder to bring a WTO dispute about something that's
more fluid and messy. And I think pushing it down to the USPTO might be better still
from that perspective. That doesn't mean you are immune from international challenge. I
also think—it's hard to imagine which country would bring that challenge in the WTO.
But the Bush doctrine of ignoring our international commitments is still alive and well in
the intellectual property circles. You don't even hear people talk much about the
constraints that TRIPS might impose here.
PROFESSOR SARNOFF: I actually have the opportunity to disagree with
everybody here on a number of topics. First, in regard to TRIPS, it depends on whether
you are a textualist or a contextualist reader of Article 27. Here we are talking about
distinctions that might say these aren't technology. Similarly, when TRIPS was
negotiated and ratified, the U.S. and most countries thought the business methods were
wholly outside the patent system, and most countries still think so. So I don't think there
is a TRIPS violation. That said, I do agree that Congress is not permitted, particularly
given the heat of the subject matter issues to ever take on subject matter. So we are not
going to get it out of Congress. I will say that I think the PTO would do a good job, and
should do a better job with rule-making power, to have some of its decisions stick. They
actually were quite restrictive on eligibility and got beaten down by the Federal Circuit
during the period in which the Supreme Court was giving the Federal Circuit free reign.
They were quite progressive in trying to restrict the expansion of the patent system, until
they just gave up. Now they are back in business, which is actually what led up to Bilski
and the other cases. In defense of the Federal Circuit here, though, I actually think they
are starting to –
PROFESSOR SAG: No.
PROFESSOR SARNOFF: I told you I disagree with everyone. I am going to
defend at least this opinion on one ground—two grounds, actually. First, you have a
nine-judge agreement on one single decision. We are looking for something that was at
least the most authoritative holding they could get, and I suspect, pretty strongly, that was
the best they could get nine votes for. That's a mastery of negotiation. Not the best
opinion. It's got lots of problems. The other thing they did right is, I think they correctly
analyzed and interpreted the Supreme Court case law, which is inconsistent and gives
little guidance, with the one exception of saying machine-or-transformation is the only
test. But even then they say it's the only test for now, which leaves it open to say it's not
the only test in another case. So I think they did the best they could. And they have
clearly gotten the message, which is—they needed to do something before the Supreme
Court did to show that they were “back with the program” of patent law.
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Finally, in regard to the reasons that 101 actually should be the threshold; it has two
really important functions that people don't understand. The first is that it directs
industrial policy. Because if you know that you can't get patents for certain types of
things, it will channel funding and channel activity in various ways. This is why,
actually, 101 should be a gatekeeper. But depending on the doctrine you adopt, it also
has the advantage of saving the PTO tremendous amounts of resources, because in many
cases, unlike for novelty, enablement, over-breadth, and obviousness, you can, from
reading the disclosure of the application itself, determine that the contribution beyond the
discovery is not patentable. So it actually is a much more administrable thing to keep
stuff out, and that's why it's a gatekeeper.
PROFESSOR MASUR: None of that is to say that if you are looking at patents, it
could be invalid on any different grounds. You have to answer the 101 question before
you answer the 103 question.
PROFESSOR SARNOFF: Well, the 101 question actually is usually easier to
answer because—at least if you are using point of novelty analysis—all you have to say
is, look, if there's no eligible invention, it's clearly an obvious invention also, right?
PROFESSOR MASUR: That doesn't mean in the infrequent case where it is more
difficult to answer than 103, that doesn't mean you should be allowed to skip over 101
and move on directly to something else.
PROFESSOR SARNOFF: That's a question for the PTO. That's an administrator
choice.
PROFESSOR MASUR: It has become a question of why Bilski is in the Supreme
Court, because we only have this case because they felt.
PROFESSOR SARNOFF: I think it should have been rejected on lack of novelty.
MS. BARNER: Let me say here from the PTO's perspective, when you look at the
difference between rejecting something on 101 and rejecting it on novelty, 101 becomes
much more of a legal issue. Does the law say you can or cannot patent this subject
matter? You are not looking at prior art cases, which are subject to dispute. When you
go to obviousness or those other things, you will have a more lengthy dispute in terms of
resources in time over where those issues may wind up. So if you were picking up an
application and you had a legal issue to deal with, and one that could require you to look
at lots of prior art, and then be subjected to lots of dispute over whether you read the prior
art right, I think your resources would say go to the 101 issue first.
PROFESSOR SARNOFF: Every time.
MR. WILLIAMS: That's fine, if applications are getting filed at all. If there's a
harsh 101 standard, and applicants say, it's not even worth it to file this thing—
MS. BARNER: Oh, if that were true.
PROFESSOR SARNOFF: Application 2008-103804, Bank of America the
assignee, a method of assessing countries for investment risk. No technology is involved;
just assign a code and a certain risk level to the different countries.
MS. BARNER: We will continue to push the edge on subject matter, which they
should. And that's part of what the Patent Office does. It, sort of, looks at these things.
So there ought to be some limiting factor so that you certainly get the resources amenable
to what you are putting in. So it certainly is intended to give people some guidance over
what is patentable and what is not. But you will continue to have people who push the
edges on those things. That's why you get growth, and where technology areas are. So I
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do think that it serves a purpose, but I don't think it would completely eradicate people
from submitting applications that don't fall within the standard.
AN AUDIENCE MEMBER: On the line drawing question that you guys were
talking about earlier, one of the things that we have seen since KSR is the Federal Circuit
taking KSR and reinterpreting it. How are we going to apply this in the chemical
context? That became a mess. And what do we do? So could we see a Bilski version
that comes out with a pretty broad test that then the Federal Circuit takes and runs with,
similar to what they have done with KSR?
PROFESSOR MASUR: I think that's likely; probably the most likely outcome.
AN AUDIENCE MEMBER: Then the fear is kicking it back to the Federal
Circuit?
PROFESSOR MASUR: The fear is that any limitations the Supreme Court wants
to impose become useless once the Federal Circuit gets a hold of it.
PROFESSOR SAG: It’s useful to try to step back and say, “What kinds of things
would people like to patent that might be more difficult for them to patent?” My reading
is that any piece of software that takes data in one form and, through some new and
useful and non-obvious process, converts it into data in a different form, that that's going
to be—that's going to be a transformation. And so even not tied to a machine, it's
probably patentable. Now, if I am wrong on that, then this is a very significant decision
for the patentability of software. And that's just one example. I think that, probably, we
are going to see the Federal Circuit, figure those things out case by case. I find it hard to
analogize—is this going to be an issue at all in chemistry? It doesn't seem like it would
be.
AN AUDIENCE MEMBER: A really important area that affects chemistry and
medicine is diagnostic medicine, and we are already seeing this happen. And there's no
question that from the viewpoint of medicine, advances in diagnostics are extraordinarily
important and profound. Just as an aside, osteoporosis, the current test today is the bone
density test. It has virtually no correlation with bone breakage, which is the thing people
are trying to solve. And so now there's a lot of investment, a lot of money that's being
focused on trying to solve those diagnostic problems as our understanding of the disease
advances. But it's exactly those types of things that are now being denied, based on
Bilski. So I wonder if you guys have any experience with some of that or some comment
on that issue.
PROFESSOR SARNOFF: The short version is, read the brief that I filed in the
LabCorp v. Metabolite case. I am opposed to patents on diagnostics where the only
invention is the recognition of the natural medical phenomenon. More basically, though,
you are just not going to get good guidance out of this case. Remember what this case is
about. This case is about a method of interaction for a particular purpose, hedging risk,
without any technological limits involved. There is no specific way of doing it, other
than that you have to enter into agreements with people. Now, how is that going to
translate into diagnostic procedure analysis, software with or without certain types of
structures—it's just not going to translate well in terms of the holding. And the
Government has told the Court, please don't say anything about those areas. So I just
don't see getting guidance on any of these issues anytime soon. The case to watch, of
course, is the ACLU case against Myriad Genetics' gene patents, which might have some
effect on medical technologies of various sorts. My guess is they will GVR the
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Prometheus v. Mayo case and send it back. But then they haven't said anything that helps
us to extrapolate from Bilski.
MR. WILLIAMS: I want to follow up real quick on the point you were making
about how 101 shapes economic behavior. And if that is our goal, it seems, to me, that
we should grant patents on things that require investment and research and development,
like new pharmaceuticals and new cell phones, or whatever. Things that companies
wouldn't do; they wouldn't put in the time and money to develop these things if they
could just be freely copied, and they would lose the entire value of their investment.
That's almost undeniably the case in things that clearly satisfy 101.
But as far as things like the Bilski claim or pure business methods, you know,
corporate structures, all of that kind of stuff, I am not sure that any company would not
look for ways to run their company better just because other companies could do it also.
I don't think it's the same kind of ex ante analysis. And I don't think there's any need to
incentivize businesses to run themselves more efficiently and do other things that
improve their bottom line at the end of the year. What we need to look out for is, we
need the benefits of companies investing in developing new inventions, whether it's new
drugs to help people in a medical way or new gadgets, or whatever, that just wouldn't
happen if patents were unavailable.
PROFESSOR SARNOFF: A two-second response. In the recent NIH report in
regard to gene patenting, the views of many of the clinicians are, for certain types of
biotechnology relating to genes, that we don’t need these patents, even though the
argument is that we need to have these patents for the investment from the corporate side.
The NIH view is that we really don't need them, and it's worse to have them for
development and innovation. So reasonable minds can differ on the issue. But that's
precisely the question, and why this is such an important issue, and why 101 drives
people emotionally in a way that most patent doctrines don't.
MR. WILLIAMS: If there's something like this properly managing your risk, all
this kind of stuff, the companies would do anyway, whether other companies are doing it
also, I just don't see how the public benefits from giving certain companies a monopoly
on such things.
PROFESSOR MASUR: I completely agree with this framework of analysis. We
should be asking the question of whether companies will be taking assertive action
regardless. And I agree with a lot of Daniel's intuitions about areas in which we do and
do not need patents. It's hard to know a priori whether we are going to absolutely need
them or not in a given field. So, it's conceivable—suppose the tax strategies we thought
were really valuable for the economy—it's conceivable companies would not innovate
tax strategies, spend the money to develop them, if, in fact, they thought a competitor was
going to steal the idea right away.
Similarly with diagnostic tools that you bring up, I don't really know. I don't have
any sort of prior intuition about whether companies will spend money to develop
diagnostic tools even if they think they can't protect them with patents or the threat of
other companies swooping in and stealing the idea is too great. We just have to know on
a technology-by-technology basis, or at least we have to have some pretty good rules of
thumb to decide. In the area of business methods, we are getting some pretty good rules
of thumb; in the area of pharmaceuticals, for instance. In a lot of cases, we have some
pretty good rules of thumb. In a lot of these areas, it's just very difficult to know. And
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the problem is it's going to be hard for a Court to sort out exactly what to do with the new
area.
PROFESSOR SARNOFF: That's the traditional role that expert administrative
agencies play; just not so much here. But, hopefully, the PTO will do so in the future,
and they will continue to develop over time greater economic expertise to analyze these
questions.
MR. BOETTICHER: If the machine-or-transformation method is upheld, does
transformation really help us at all? It seems like a pretty vague standard, I mean, even
for the law. And you touched upon this a little bit. I mean, is it really going to be a
helpful standard or do you think the Supreme Court will bump that down to the Federal
Circuit as well, and we will keep puttering along with it for awhile?
MR. WILLIAMS: What I would say about the transformation prong of this test is
that I think it would be great and very useful and intellectually sound if it was actually
compartmentalized to things that transform physical things into other physical things.
But when it gets watered down by—I can't remember the name of the case at the
moment. It’s that case about where you take data that was gathered by an x-ray scanner,
and you turn it into this display that shows different parts of somebody's leg bone or
something. There's a problem to say that that satisfies the transformation test because the
data represents something in the physical world, to me, just makes that test—it's just
watered down to the point where it can almost mean anything.
Apparently, Bilski doesn't satisfy it because these are just legal risks and business
relationships, and all that kind of thing. But for that case in particular, I am a computer
guy so I am kind of in favor of a positive view of software patents and general purpose
computers, and things like that. I would have just said it satisfies the machine prong of
the test because, number one, it involves this x-ray scanner, which, to me, is particular
enough. But even if it didn't, to me, a general purpose computer with particular software
A, that's a different machine, to me, than a general purpose computer with particular
software B on it. It's just the fact that it's manipulating electrons and carrying out
instructions and all this stuff and it's not gears and very mechanical type things. To me,
it's just a bias against software and computers. And to say that those aren't two different
machines is crazy. Basically, what the inventors in that case built was a machine that
could take that data and turn it into some useful display, and that was a machine that
worked better than machines that came before it, or a machine that didn't exist before
their invention. And so to try to shoehorn that into a transformation test just makes the
whole analysis start to suffer from intellectual lack of integrity.
MR. NARAYEN: I kind of wanted to follow up on Professor Masur's last point. It
sounded like—correct me if I am wrong. It sounded like the lines or the factor that really
matters in Subject Matter Analysis 101 is the field of endeavor; like that's the best way to
look at it. So like you said, pharmaceuticals, we have got a pretty good rule of thumb.
They need lots of protection. In business methods, I think a lot of people agree that you
don't. People would continue creating innovative new business methods, because that's
not where they derive their profits. But if that's true, isn't the sort of test that you are
trying to construct need to span all these fields of endeavor, isn't that the entirely wrong
way to go about it? If you were being intellectually honest, you would say, okay, 101 is
about fields of endeavor. Some fields of endeavor, we think, don't need the help of the
patent protection, and some do. The Supreme Court is not an expert in it. Neither is the
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Federal Circuit. So maybe we leave it to some administrative body that can, sort of,
develop expertise based on the experience with patents and different fields of endeavor. I
know that's kind of a long, meandering question. But is that what, sort of, you were
getting at?
PROFESSOR MASUR: Yes. I mean, I think you have summarized my views
pretty accurately. I guess I would say it's not that what the Courts are doing is
intellectually dishonest or the wrong idea from the beginning. It's second best. It's the
best mediocre proxy for what we really ought to be caring about. It would be much better
if we could get directly at the question. The two things standing in the way are, number
one, TRIPS is not very helpful; number two, the fact that common law courts just aren't
very well equipped to do this sort of thing. They are very good at verbal formulations
and general testament to cover all fields. And they are not going to be more specific.
It's probably not a surprise that patent law has the technological neutrality norm
where you are not supposed to make field—technological field level distinction. It's
probably due in part to the fact that courts aren't equipped to make those choices either
from the position of expertise or from a matter of the sorts of rules that courts aren't
skilled at coming up with in courts of common law. I don't want to accuse them of bad
faith. I just think it's not the best way of getting at the issues that we care most about.
MR. WILLIAMS: I think that fields of endeavor—you would have huge problems.
There has to be some business methods that can be enabled and are new and not obvious
that some other company can take and make their business work better because of it, and
some that are just like—perhaps like Bilski; you know, just stated so abstractly that they
don't—that they couldn't even be enabled; that they couldn't help anyone else but the
expert who knows how to do this. This is the type of claim that you just couldn't make
someone a good, smart, businessman by handing them this claim. And so I don't think
that the subject matter exclusions will happen, and I don't think that they should happen,
because it's inevitable that some category will have some applications that clearly are a
technological advance, and some that clearly are not or would have no chance of passing
the other requirements of the patent statute, 112, 102, 103.
PROFESSOR MASUR: If we thought we could make the right distinction by
using methods other than Section 101, then we wouldn't even have to worry about
Section 102 or 103. We thought we could solve this by looking at novelty and
enablement. Then it doesn't matter what we do with 101. We are going to get the right
patents, and it's all irrelevant. The problem, why this has arisen, is we think those tools
have not been adequate to get us the right patents in a lot of different fields without some
input from Section 101. We need something in Section 101 to curb this problem. What
we have now is the situation in which patents across all of these fields are very widely
available.
The question we should ask is, as between that circumstance or a circumstance in
which patents in certain fields are not at all available or circumstances in which some
patents in some fields are, maybe, harder to get, which of them is best for the economy
for the country generally? I think if you ask people right now, what would be better, the
current system of patenting or a world in which no patents on business method software
were available, you would get a lot of votes for the latter view; that getting rid of them
consistently would be better for the economy across the board. So if we can find some
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sort of middle ground, maybe that's the direction we should go. The goal is to find a
middle ground. The Court is not going to be particularly well equipped to do that either.
PROFESSOR SAG: I think one of the issues that tends to get overlooked in this
discussion of field by field and patent by patent, is that the basic unit of analysis is not the
patent; it's the claim. And there is a structural problem with the patent system in that
almost every patent starts with garbage, and ends with something that's entirely
defensible. It starts with something really broad and really abstract that is probably not
enabled or is probably not novel, or maybe even not proper subject matter. And the PTO
is under a lot of pressure. The competence of their examiners is probably distributed
along a bell curve, like almost everything else. A lot of bad claims get through in the
context of patents that were actually quite defensible. But then we are starting to develop
a very liquid secondary market for patents, where entrepreneurs seek out those things that
have issued, that have a presumption of validity, and then use them to impose an
innovation tax, is one perspective, on companies that are actually out there, making
things, engaging in research and development.
So it would be good if we got something out of the Bilski decision, and the
decisions that follow it, that actually, sort of, lift the standard of patents generally. We
are not just talking about excluding particular inventions and particular fields. We are
also talking about changing the way things are claimed, and hopefully with less bad,
vague claims in the system. And many of the problems we are dealing with today are a
leftover of the late '90s when, with all due respect, the PTO dropped the ball and went
through just a wave of junk. And I am not sure that Bilski is going to help us out here,
but my hope is that it would.
PROFESSOR SARNOFF: It drives you back again to ask, what's the invention in
the claim? Because the dependent claim’s structural addition really may not be any
creative part of the invention. But it is part of the claim you have to analyze? That is the
entire question.
MR. BOETTICHER: All right. So on that note, I think we will end this panel.
And I would like to thank our panelists very much. That was a great discussion. And we
clearly have a lot of talent here. For the next part, we are going to go upstairs to Room
540 where we are going to have lunch, and our keynote speaker, Deputy Sharon Barner,
will give a speech. Thank you very much.
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